The study assessed vaccinated mice sera for efficacy against key coronavirus variants, including Delta and Omicron.

The study found that mice immunized with different formulations of the vaccine elicit high titers of antibodies that neutralize SARS-CoV-2 variants VIC31 (reference strain), Delta, and Omicron variants of coronavirus.

As per the study, there was an average 14.4-fold reduction in neutralization against the Omicron variant for one formulation of the Mynvax vaccine and a 16.5-fold reduction for another formulation, compared to VIC31.

Source: IANS